Skip to main content
Signal8
Launch Terminal

MEDICINOVA INC (MNOV)

MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, currently being investigated for a range of neurological conditions. These include primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and various forms of substance dependence and addiction. The company's portfolio also comprises MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist aimed at treating acute asthma attacks; MN-001 (tipelukast), an orally available small molecule designed for fibrotic disorders like nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent intended for solid tumor oncology. MediciNova has established strategic partnerships with companies such as Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Angiogene Pharmaceuticals Ltd., and Meiji Seika Kaisha Ltd. Established in 2000, the company's headquarters are situated in La Jolla, California.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

MediciNova, Inc. logo

MediciNova, Inc.

NASDAQ:MNOVHealthcare
+0.00%$1.40
AH$1.40+0.00%vs close
Mkt Cap$68.91M
Float47.81M
O/S49.22M
Vol
$ Vol
RVOL
Inst Own10.5%
SI0.6%
Earnings
Dilution
MediciNova, Inc. logoNASDAQ:MNOV$1.40+0.00%
Phase Distribution
17 lead-sponsored trials·2 active·14 completed
Phase 14
Phase 1/22
Phase 210
Phase 2/31
(4 more as collaborator)
Status Overview
Active, not recruiting2
Completed14
Stopped1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 2/3
    Active, not recruiting

    Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS

    MN-166, placebo

    Amyotrophic Lateral Sclerosis

    Enrollment
    234
    Start
    May 2020
    Primary Completion
    Apr 2027est.
    Completion
    Apr 2028est.
    NCT04057898
  • Phase 2
    Completed

    Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis

    MN-001 BID, MN-001

    Interstitial Cystitis

    Enrollment
    296
    Start
    May 2005
    Primary Completion
    Oct 2006
    Completion
    Oct 2006
    NCT00295854
  • Phase 2
    Completed

    Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma

    MN-221, MN-221

    Asthma

    Enrollment
    17
    Start
    Feb 2008
    Primary Completion
    Jul 2008
    Completion
    Jul 2008
    NCT00679263
  • Phase 2
    Terminated

    Study Evaluating the Safety and Effects of MN-221 in Subjects Experiencing an Acute Exacerbation of Asthma

    Dose Group 1, MN-221 placebo

    Asthma, Status Asthmaticus

    Enrollment
    29
    Start
    Jun 2008
    Primary Completion
    Mar 2009
    Completion
    Mar 2009
    NCT00683449
  • Phase 2
    Completed

    Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of Asthma

    MN-221, Placebo

    Asthma

    Enrollment
    176
    Start
    Mar 2009
    Primary Completion
    Mar 2012
    Completion
    Mar 2012
    NCT00838591
  • Phase 2
    Completed

    Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis

    ibudilast, Placebo oral capsule

    Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive

    Enrollment
    255
    Start
    Nov 2013
    Primary Completion
    May 2017
    Completion
    Dec 2017
    NCT01982942
  • Phase 2
    Completed

    Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)

    Placebo (for MN-166), MN-166

    Amyotrophic Lateral Sclerosis

    Enrollment
    70
    Start
    Sep 2014
    Primary Completion
    Aug 2017
    Completion
    Dec 2017
    NCT02238626
  • Phase 2
    Completed

    Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary Fibrosis

    MN-001, Placebo

    Idiopathic Pulmonary Fibrosis, IPF

    Enrollment
    15
    Start
    Mar 2016
    Primary Completion
    Dec 2020
    Completion
    Mar 2022
    NCT02503657
  • Phase 2
    Completed

    Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects

    MN-001

    Non-alcoholic Steatohepatitis, Hypertriglyceridemia +2

    Enrollment
    19
    Start
    Mar 2016
    Primary Completion
    May 2018
    Completion
    Oct 2019
    NCT02681055
  • Phase 2
    Completed

    Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS

    Ibudilast, Placebo

    Pneumonia, Viral

    Enrollment
    34
    Start
    Jan 2021
    Primary Completion
    Jun 2022
    Completion
    Aug 2024
    NCT04429555
  • Phase 2
    Active, not recruiting

    MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia

    MN-001, MN-001 placebo

    Diabetes Mellitus, Type 2, Hypertriglyceridemia +1

    Enrollment
    40
    Start
    Aug 2022
    Primary Completion
    Dec 2026est.
    Completion
    Dec 2026est.
    NCT05464784
  • Phase 1/2
    Completed

    A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS)

    ibudilast, Ibudilast

    Amyotrophic Lateral Sclerosis

    Enrollment
    35
    Start
    May 2016
    Primary Completion
    Dec 2019
    Completion
    Jun 2020
    NCT02714036
  • Phase 1/2
    Completed

    Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma

    MN-166, Temozolomide

    Glioblastoma, Recurrent Glioblastoma +2

    Enrollment
    64
    Start
    Dec 2018
    Primary Completion
    Aug 2023
    Completion
    Aug 2023
    NCT03782415
  • Phase 1
    Completed

    Evaluate the Safety of MN-221 in Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

    MN-221 (Dose Group 1), MN-221 (Dose Group 2)

    Chronic Obstructive Pulmonary Disease

    Enrollment
    48
    Start
    Nov 2009
    Primary Completion
    Mar 2010
    Completion
    Mar 2010
    NCT01013142
  • Phase 1
    Completed

    Safety Study to Evaluate MN-221 in Chronic Obstructive Pulmonary Disease (COPD) Patients

    MN-221, Placebo

    Chronic Obstructive Pulmonary Disease

    Enrollment
    19
    Start
    Mar 2012
    Primary Completion
    May 2012
    Completion
    May 2012
    NCT01551316
  • Phase 1
    Completed

    Study of MN-166 (Ibudilast) Extended Release Tablet Formulations Compared With Capsules in Healthy Volunteers

    MN-166

    Healthy Volunteers

    Enrollment
    28
    Start
    Apr 2018
    Primary Completion
    Jul 2018
    Completion
    Sep 2018
    NCT03533387
  • Phase 1
    Completed

    Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy Volunteers

    MN-166

    Healthy Volunteers

    Enrollment
    12
    Start
    Jun 2019
    Primary Completion
    Jul 2019
    Completion
    May 2020
    NCT04054206
Search ClinicalTrials.gov for “Medicinova”